
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Discovery Platform
Recipient : Hanall Biopharma
Deal Size : $300.0 million
Deal Type : Licensing Agreement
HanAll Signs Licensing Agreement with Turn Biotechnologies for Eye and Ear Treatments
Details : The collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's cellular reprogramming technology to create innovative therapies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 28, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery Platform
Recipient : Hanall Biopharma
Deal Size : $300.0 million
Deal Type : Licensing Agreement
